ICLR vs NTRB vs FTRE Stock Comparison

Icon, NutriBand and Fortrea Holdings Prices as of Oct 29, 2026 Peers: Industry group
1 more company in this comparison (TMO) Create a free account to keep reading and compare up to 10 companies.
ICLR Icon Plc
$215.48 +26.5% 1M +29.8% 1Y
Market cap
$16.50B
P/E
37.7x
Revenue (TTM)
$8.23B
Div. yield
–
Contract Research Healthcare
5 wins
NTRB NutriBand Inc.
$6.64 -19.5% 1M -4.2% 1Y
Market cap
$80.71M
P/E
–
Revenue (TTM)
$1.62M
Div. yield
–
Generic Drugs Healthcare
3 wins
FTRE Fortrea Holdings Inc.
$23.14 +17.2% 1M +121.6% 1Y
Market cap
$2.23B
P/E
–
Revenue (TTM)
$2.67B
Div. yield
–
Contract Research Healthcare
2 wins

Head to Head

10 decided of 12

Icon leads on 5 of the 12 questions below (Icon 5, NutriBand 3, Fortrea Holdings 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionICLRNTRBFTRELeader
Larger companyMarket capitalisation $16.50B $80.71M $2.23B ICLR
Cheaper on earningsLower P/E, profitable companies only 37.7x -11.6x -32.2x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 21.0x 4.0x 28.6x NTRB
Faster revenue growthRevenue growth, trailing twelve months +1.8% -37.3% -3.4% ICLR
More profitableNet margin, trailing twelve months 5.4% -430.4% -2.6% ICLR
Better return on capitalReturn on invested capital 4.7% — 0.8% ICLR
Less leveragedLower net debt / EBITDA 2.3x 0.5x 9.1x NTRB
Higher dividend yieldTrailing dividend yield — — — –
Better 1-year returnPrice return, last 12 months +29.8% -4.2% +121.6% FTRE
Better 5-year returnAnnualised price return, 5 years -5.6%/yr +4.3%/yr — NTRB
Less volatileAnnualised volatility, 1 year 75.0% 79.1% 71.4% FTRE
Higher overall scoreMean of the five percentile scores vs peers 81/100 51/100 53/100 ICLR

Percentile Scorecard

ICLRNTRBFTRE

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisICLRNTRBFTRE
Valuation 100 #1 of 11 56 #278 of 624 90 #2 of 11
Growth 70 #4 of 11 43 #344 of 601 60 #5 of 11
Profitability 80 #3 of 11 36 #346 of 541 60 #5 of 11
Financial Health 75 #4 of 13 68 #207 of 647 0 #13 of 13
Shareholder Returns – – –
Overall 81 51 53
  • ICLR ranked among 13 companies in Pharma Services
  • NTRB ranked among 671 companies in Pharmaceuticals and Biotechnology
  • FTRE ranked among 13 companies in Pharma Services

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodICLRNTRBFTRESPY
1 month +26.5%-19.5%+17.2% +0.7%
3 months +30.2%+128.2%+21.3% +3.7%
6 months +82.1%+71.6%+101.2% +7.1%
Year to date +18.3%+46.3%+34.1% +12.8%
1 year +29.8%-4.2%+121.6% +11.9%
3 years -9.5%+210.3%-15.2% +85.2%
3 years, per year -3.3%+45.9%-5.4% +22.8%
5 years -24.9%+23.6%— +67.6%
5 years, per year -5.6%+4.3%— +10.9%
10 years +168.3%—— +262.0%
10 years, per year +10.4%—— +13.7%

Risk

MeasureICLRNTRBFTRESPY
Volatility, 1Y 75.0%79.1%71.4% 12.7%
Downside volatility, 1Y 87.7%73.9%65.5% 12.6%
Beta vs S&P 500, 1Y 1.471.032.04 1.00
Return / volatility, 1Y 0.40-0.051.70 0.94
Max drawdown, 5Y -76.9%-77.7%-89.9% -25.4%
From 52-week high 0.0%-26.1%-10.6% -1.2%
52-week high $215.48$8.99$25.88 $779.14
52-week low $80.08$2.81$8.87 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleICLRNTRBFTRE
P/E now vs peer median 37.7xmedian 36.6x -11.6xmedian 17.8x -32.2xmedian 36.6x
P/S now vs peer median 2.0xmedian 2.6x 49.9xmedian 9.1x 0.8xmedian 2.6x
EV/EBITDA now vs peer median 17.4xmedian 31.1x -11.2xmedian 15.0x 33.5xmedian 31.1x
P/FCF now vs peer median 19.3xmedian 21.8x -22.2xmedian 21.7x 13.2xmedian 21.8x
P/B now vs peer median 1.8xmedian 3.1x 15.1xmedian 2.2x 4.2xmedian 3.1x
PEG now vs peer median -15.86median 2.05 -14.12median 0.35 0.53median 2.05

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsICLRNTRBFTRE
Revenue $8.23B $1.62M $2.67B
Gross profit $1.93B $536.12K $533.40M
Operating income $718.25M -$7.05M $12.80M
Net income $448.66M -$6.96M -$68.70M
Free cash flow $857.06M -$3.63M $169.00M
R&D – $1.21M –
EPS (diluted) $5.68 $-0.57 $-0.68
Cash & equivalents $808.98M $3.42M $220.60M
Total debt $3.38B $647.66K $1.06B
Shares (diluted) 78.97M 12.16M 101.20M
Enterprise value $13.27B $63.40M $1.52B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricICLRNTRBFTRE
P/E 37.7x -11.6x -32.2x
P/FCF 19.3x -22.2x 13.2x
P/Operating cash flow 16.1x -22.2x 11.1x
P/S 2.0x 49.9x 0.8x
P/B 1.8x 15.1x 4.2x
P/Tangible book 2.7x 15.6x -56.2x
EV/EBITDA 17.4x -11.2x 33.5x
EV/EBIT 26.5x -11.0x 239.7x
EV/Revenue 2.3x 47.9x 1.2x
EV/FCF 22.2x -21.3x 18.2x
EV/Operating cash flow 18.6x -21.3x 15.2x
PEG (3Y EPS CAGR) -15.86 -14.12 0.53

Growth

14 metrics
MetricICLRNTRBFTRE
Revenue growth (1Y) 1.8% -37.3% -3.4%
Revenue CAGR (3Y) 0.9% -10.8% 0.4%
Gross profit growth (1Y) -13.4% -39.5% 3.9%
Gross profit CAGR (3Y) -6.5% -16.5% -8.5%
Operating income growth (1Y) 53.9% 32.3% 101.4%
Operating income CAGR (3Y) -7.0% -15.3% -43.3%
Net income growth (1Y) 55.9% 32.2% 93.2%
Net income CAGR (3Y) -4.4% -14.8% -47.8%
EPS growth (1Y) 30.1% 80.0% 93.9%
EPS CAGR (3Y) -2.4% 0.8% -60.7%
Operating cash flow growth (1Y) -9.9% 25.9% 13,353%
Operating cash flow CAGR (3Y) 15.8% -5.7% 5.2%
Free cash flow growth (1Y) -11.1% 26.6% 1,400%
Free cash flow CAGR (3Y) 18.4% -5.5% 10.8%

Profitability

14 metrics
MetricICLRNTRBFTRE
Gross margin 23.4% 33.1% 20.0%
EBITDA margin 13.3% -426.5% 3.4%
Operating margin 8.7% -435.6% 0.5%
Pretax margin 6.3% -430.4% -2.0%
Net margin 5.4% -430.4% -2.6%
FCF margin 10.4% -224.5% 6.3%
Operating cash flow margin 12.5% -224.5% 7.6%
Return on equity 7.6% -123.0% -13.0%
Return on assets 4.3% -105.6% -2.5%
Return on invested capital 4.7% – 0.8%
Return on capital employed 5.3% -123.9% 0.7%
Asset turnover 0.5x 0.2x 1.0x
Cash conversion (OCF / net income) 2.3x 0.5x -2.9x
Stock comp / revenue 1.1% 204.1% 1.9%

Financial Health

11 metrics
MetricICLRNTRBFTRE
Debt / assets 20.8% 2.4% 38.5%
Debt / equity 0.4x 0.0x 2.0x
Net debt / EBITDA 2.3x 0.5x 9.1x
Debt / FCF 3.9x 0.0x 6.2x
Liabilities / assets 43.8% 15.3% 80.6%
Equity / assets 56.2% 84.7% 19.4%
Interest coverage 3.4x -339.3x –
Current ratio 1.3x 4.2x 1.0x
Quick ratio 0.9x 3.8x 0.9x
Cash ratio 0.3x 3.8x 0.2x
Altman Z-score 2.28 36.48 0.86

Shareholder Returns

7 metrics
MetricICLRNTRBFTRE
Dividend yield – – –
Net buyback yield 2.3% – –
Shareholder yield 2.3% – –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusICLRNTRBFTRE
Forward P/E 21.0xFY2026 4.0xFY2026 28.6xFY2026
EPS, next fiscal year $10.25FY2026 $1.65FY2026 $0.81FY2026
EPS growth, next FY -18.2%FY2026 – +88.4%FY2026
EPS growth, the year after +22.2% +112.1% +22.2%
Revenue, next fiscal year $8.52BFY2026 $90.32MFY2026 $2.77BFY2026
Revenue growth, next FY +3.2%FY2026 +4,334.5%FY2026 +1.7%FY2026
Revenue growth, the year after -3.2% +109.8% -3.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersICLRNTRBFTRE
Held by institutions 100.0% – 100.0%
Institutions holding 423 – 330
Change in shares held, QoQ +5.5% – -0.2%
Institutions buying 234 – 140
Institutions selling 138 – 108
Buyers to sellers 1.70 – 1.30

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ICLRNTRBFTRE
ICLR 1.00 0.17 0.47
NTRB 0.17 1.00 0.16
FTRE 0.47 0.16 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ICLR, NTRB and FTRE?

Icon (ICLR) is the largest by market capitalisation: Icon (ICLR) $16.50B, NutriBand (NTRB) $80.71M, Fortrea Holdings (FTRE) $2.23B.

Which company is growing faster?

Icon (ICLR) grew revenue fastest over the trailing twelve months: Icon (ICLR) +1.8%, NutriBand (NTRB) -37.3%, Fortrea Holdings (FTRE) -3.4%.

Which company is more profitable?

Icon (ICLR) has the highest net margin (Icon (ICLR) 5.4%, NutriBand (NTRB) -430.4%, Fortrea Holdings (FTRE) -2.6%). On return on invested capital, Icon (ICLR) leads (Icon (ICLR) 4.7%, Fortrea Holdings (FTRE) 0.8%).

Which stock has performed better?

Over the past year Fortrea Holdings (FTRE) returned the most: Icon (ICLR) +29.8%, NutriBand (NTRB) -4.2%, Fortrea Holdings (FTRE) +121.6%. Over five years, NutriBand (NTRB) compounded fastest (Icon (ICLR) -5.6%/yr, NutriBand (NTRB) +4.3%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Fortrea Holdings (FTRE) has been the steadiest (Icon (ICLR) 75.0%, NutriBand (NTRB) 79.1%, Fortrea Holdings (FTRE) 71.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ICLR, NTRB and FTRE?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Icon (ICLR) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.